Enterprise Europe Network

Novel antibiotic and antitumor agent produced by the marine actinobacterium Streptomyces althioticus

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20190326002
Published
26/03/2019
Last update
28/03/2019
Expiration date
04/10/2019

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Pharmaceutical Products / Drugs
Virus, Virology/Antibiotics/Bacteriology
Microbiology
Microbiology
Oncology
Pharmaceuticals/fine chemicals
Marine products
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish research group has patented a novel bacterial strain of Streptomyces althioticus, which is able to efficiently produce by fermentation cytotoxic compounds of the family of desertomycins. Specifically, this strain is producing a new desertomycin, having cytotoxic activity against different tumour cell lines and antibacterial activity against pathogenic bacteria. Companies in microbiology and pharmacy are sought to develop applications of the described invention under license agreements.

Description

Description: 

Marine environments are emerging as a source of new natural products of pharmacological importance and intertidal macroalgae have revealed as a medium that should be investigated to discover structurally unique natural products with biomedical relevance. Due to the increasing need for new antitumor agents with improved activity, fewer undesirable side effects and greater selectivity compared to the current drugs in use in the fight against cancer and to the increasing emergence of current antibiotic-resistant pathogenic bacteria, it is necessary to develop new antitumor agents with improved pharmacological properties and of new antibiotics with potential biomedical treatment or prevention of infectious diseases caused by pathogenic bacteria. It is also necessary to have simple, short and economical methods for obtaining such compounds with antitumor and / or antibacterial activity.

Researchers from a Spanish university working in microbiology provide a novel bacterial strain of Streptomyces althioticus that has been isolated from its natural environment, which is able to efficiently produce by fermentation compounds of the family of desertomycins. Specifically, this strain is producing a new desertomycin, which has cytotoxic activity against breast and colon tumour cell lines and also strong antibiotic activity against Mycobacterium tuberculosis and other clinically relevant pathogens.

The present invention thus relates to a bacterial strain of Streptomyces althioticus, to a supernatant or extract of a culture of such bacterial strain, to the use of the bacterial strain for the production of certain desertomycin, to a process for obtaining said desertomycin, to a pharmaceutical or cosmetic composition, to the manufacture of a medicament for the treatment of cancer and for the treatment and / or prevention of bacterial infections or for removal and / or prevention and / or inhibition of bacterial biofilm formation, preferably on inert surfaces, i.e. ex vivo.

The researchers would like to reach license agreements with companies operating in the clinical microbiology and pharmacy fields with the aim to develop applications of the described technology.

Advantages & innovations

Cooperation plus value: 
The present invention represents a solution to the need for new antitumor compounds with biomedical potential in the treatment or prevention of infectious diseases caused by Gram positive and Gram negative pathogenic bacteria. It also represents a solution to the need for simple, short and economic procedures for obtaining said compounds with antitumor and antibacterial activity as the method of the invention allows to produce such compound by fermentation with an actinobacteria, rather than by chemical synthesis, which is a more complex, lengthy and costly process. In this regard, in biotechnological processes involving obtaining structurally complex natural products, such in the case of desertomycins, the production by fermentation using the producing microorganism is the preferred method because it is simpler, shorter and cheaper than the organic synthesis procedure.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
Type of partner sought: industry. Area of activity of the partner: companies working in clinical microbiology and pharmacy fields. Task to be performed: applications of the described technology.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500